Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
Skin Pharmacol Physiol. 2009;22(6):322-34. doi: 10.1159/000241302. Epub 2009 Sep 25.
Primary cutaneous lymphomas (CLs) originate in the skin and should be differentiated from secondary skin infiltrates, which are manifestations of lymphomas of nodal or extranodal origin. These rare diseases include various lymphoproliferative disorders: cutaneous T-cell lymphomas, cutaneous B-cell lymphomas and some rare subtypes. As definitive cure is often not possible, it is important to control the disease and alleviate symptoms. Patients with early-stage disease limited to the skin usually require skin-directed therapies using topical agents including corticosteroids, chemotherapeutic drugs, bexarotene gel, electron beam therapy and phototherapy. Each of these are effective; however, all have some disadvantages and are associated with significant adverse events. In the field of skin-directed therapies there are interesting developments using antineoplastic compounds, the retinoid tazarotene, imiquimod, gene therapy products (adenovirus vector expressing gamma-interferon), the monoclonal anti-CD20 antibody rituximab, photodynamic therapy and 308-nm excimer laser to mention a few. This review highlights some of the promising new and experimental local therapies for primary CLs and focuses on their efficacy and side effects.
原发性皮肤淋巴瘤（CL）起源于皮肤，应与继发性皮肤浸润相区别，后者是淋巴结或结外起源的淋巴瘤的表现。这些罕见疾病包括各种淋巴增生性疾病：皮肤 T 细胞淋巴瘤、皮肤 B 细胞淋巴瘤和一些罕见亚型。由于通常无法治愈，因此控制疾病和缓解症状非常重要。早期局限于皮肤的患者通常需要使用皮肤靶向治疗，包括局部应用皮质类固醇、化疗药物、贝沙罗汀凝胶、电子束治疗和光疗。这些方法都有效；然而，它们都有一些缺点，并与严重的不良反应有关。在皮肤靶向治疗领域，使用抗肿瘤化合物、类视黄醇他扎罗汀、咪喹莫特、基因治疗产品（表达γ干扰素的腺病毒载体）、单克隆抗 CD20 抗体利妥昔单抗、光动力疗法和 308nm 准分子激光等方法有一些很有前途的新方法和实验性局部治疗。这篇综述强调了一些治疗原发性 CL 的有前途的新的和实验性的局部治疗方法，并重点介绍了它们的疗效和副作用。
